Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders back in September.
Vitae Pharmaceuticals, Inc. (“Vitae”) is developing VTP-43742 for the treatment of autoimmune disorders. Patient Worthy reports this Phase I trial information because of its relevance to ankylosing spondylitis (a musculoskeletal disorder) in particular, but research and development intentions span to include: psoriasis, multiple sclerosis, psoriatic arthritis, inflammatory bowel disease, rheumatoid arthritis and various arthropathies.
Street Insider reported on March 23rd that Vitae will “require substantial future capital in order to complete the remaining clinical development (and research into) VTP-43742, VTP-38543, VTP-36951” – as drug candidates for rare and orphan disorders.
Vitae’s mission is to develop new therapies for diseases with significant unmet medical needs. Patient Worthy is following news about their RORyt Program closely.
- VTP-43742 is in Phase II for the treatment of psoriasis. Vitae plans to report the proof-of-concept clinical efficacy results in first quarter of 2016 and a positive proof-of-concept, initiates the Phase II trial for psoriasis in second half of 2016.
- VTP-38543 is in phase 2a proof of concept for the topical treatment for eczema. It is a Liver X Receptor (LXR) selective agonist different from other approved atopic dermatitis drugs because it repairs the outer layer of skin, improving the barrier function. Preclinical studies have demonstrated clinical superiority to existing therapy. Read more here.
- VTP-36951 for the treatment and prevention of Alzheimer’s disease, which was previously being developed by Boehringer Ingelheim, pursuant to a research collaboration and license agreement.
